The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Celgene Corp  (CELG) Trade Now »     Rate CELG  -  Discuss CELG  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
86.0%
Top:
100.0%
Rate CELG:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

CELG: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Highly Defensive Index: Opportunities in Healthcare Graphic_rating_buy CELG
Mikerun
73%
 +28.14%
in 209 days
The ETF Innovators Highly Defensive Index contains 32 market cap leading companies from the defensive industry groups (A-K) specified below in addition to one position reserved for the SPDR Gold Trust (GLD) as a hedge against long-term inflation and global currency devaluation. Since I last wrote about the index two months ago, Genentech has been acquired by Roche (RHHBY.PK) and the number of securities has been reduced from 40 to 33.
 
Table with Highly Defensive Index stats and benchmark funds:
<> http://biomedreports.com/articles/most-popular/805-highly-def... ...
By  Mike Havrilla   (+1.04%  risk: conservative)  04/13/09 Comment


New Index of Cancer Diagnostic and Therapeutic Stocks Graphic_rating_buy CELG
Mikerun
73%
 +0.00%
in 12 hours
(closed on 04/13/09)
By Mike Havrilla on 4/12/09 at BioMedReports.com
 
The table at the link below includes statistics for the 40 companies in the ETF Innovators Emerging Cancer Diagnostic and Therapeutic Stock Index, which is featured at BioMedReports.com in the health indexes section of the site. The index will track the performance of stocks with market caps below $200M at the inception date of 4/12/09 from a starting value of 2,632.
 
 
<> A World Health Organization report released last year es...
By  Mike Havrilla   (+1.04%  risk: conservative)  04/12/09 Comment


Nine for '09 Stock Picks Start Strong Graphic_rating_buy CELG
Mikerun
73%
 -20.79%
in 94 days
(closed on 04/12/09)

Nine for '09 Stock Picks Start Strong

<>

The nine stock picks I posted in mid-December are off to a strong start in the new year, with seven of the stocks registering gains and a 14.5% gain for the group as an equal-weight average versus a 1.1% gain for the S&P 500 SPDR ETF (SPY). Click on any of the links below for my most recent articles on each company.

The four smallest, defensive healthcare stock picks are leading the group with an average gain of 30.6% thanks to an 87.3% gain for Javelin Pharma (JAV) and a 42.9% gain for Caraco Pharma (CPD) while...
By  Mike Havrilla   (+1.04%  risk: conservative)  01/08/09 Comment


My UpDown Virtual Investing Portfolio Graphic_rating_buy CELG
Mikerun
73%
 -7.62%
in 7 days
(closed on 01/08/09)

My UpDown Virtual Investing Portfolio

<>



Start earning real money with zero risk while improving your trading skills and strategies at the UpDown Virtual Investing website -- just click on the image above or any of the text links to the site in this article to sign up today. My stats and profile are featured in the accompanying table and on my blog site below the last posted entry. I started trading at the UpDown on 11/23/08 with a gain of 32.5% through today -- my profile name on the site is 'ETFinnovators' with a portfolio of long positions and link...
By  Mike Havrilla   (+1.04%  risk: conservative)  01/01/09 Comment


Small, Defensive '09 Stock Picks Are Soaring Graphic_rating_buy CELG
Mikerun
73%
 +3.54%
in 13 days
(closed on 01/01/09)

Small, Defensive '09 Stock Picks Are Soaring

<>

The nine defensive stock picks I wrote about last week are off to a very strong start, posting a 7.4% gain as an equally-weighted average compared to a 1% gain for the S&P 500 SPDR ETF (SPY). The biggest gains came from the smallest companies in the index – Caraco Pharma (CPD) was up 40% while Javelin Pharma (JAV) increased by 19% in the past week and has more than doubled since I first wrote about it in early December .

Despite a drop in shares of Altria (MO) over the past week, I have added to ...
By  Mike Havrilla   (+1.04%  risk: conservative)  12/18/08 Comment




From the Blogosphere

Celgene (CELG): Bet on biotech for 'offense and defense'

Filed under: Newsletters, Stocks to Buy

"I am recommending Celgene (NASDAQ: CELG) as part of an 'offense-defense' thesis," says Ian Wyatt. In Top Stock Insights, he reviews the leading biotechnology company.

Wyatt explains, "Celgene engages in the discovery of therapies designed to treat cancer and immune inflammatory related diseases. They have a number of products at the commercial stage including REVLIMID, THALOMID and VIDAZA.

<>"Celgene is also researching stem cells derived from the human placenta as well as from the umbilical cord, thus tapping into a promising new technology while avoidi...
By  Blogging Stocks    10/27/09 Comment


Cord Blood Stocks: Cord Blood Transplants May Provide Cures for Babies While Still in the Womb
Tradinggoddess
 5 %
Duke University is studying the use of cord blood transplants in babies while still in the womb, in order to treat various metabolic disorders. The U.S. Food and Drug Administration has given approval for clinical trials.

Cord blood is blood that comes from umbilical cords, and contains a large amount of hematopoietic stem cells. Specialized cord blood banks are available to store this blood. Cord blood stem cells are considered far superior to stem cells from bone marrow. Many parents have their newborn's cord blood preserved in the event it may be needed at some point in the future for tr...
By  Trading Goddess   (-46.13%  risk: aggressive)  10/22/09 Comment


Celgene (CELG): Bet on biotech
16%

"I am recommending Celgene (NASDAQ: CELG) as part of an 'offense-defense' thesis," says Ian Wyatt. In Top Stock Insights, he reivews the leading biotechnology company.

"Celgene engages in the discovery of therapies designed to treat cancer and immune inflammatory related diseases. They have a number of products at the commercial stage including REVLIMID, THALOMID and VIDAZA. 

<>"Celgene is also researching stem cells derived from the human placenta as well as from the umbilical cord, thus tapping into a promising new technology while avoiding the political and ethical questions dogging others ...
By  The Stock Advisors   (-19.48%  risk: moderate)  10/21/09 Comment


Celgene is poised to break-out to the upside Graphic_rating_buy CELG
-5.38%
in 30 days

Filed under: Stocks to Buy

Celgene (NASDAQ: CELG), is performing as expected, hence I'm Reiterating my Buy rating for company, first recommended on June 19, 2009 at a price of $46.94. If you bought CELG in June, you're up about 20%.

Look for a 15-20% FY2009 revenue increase in CELG, boosted by cancer treatments Revlimid's and Vidaza's sales. Further, pipeline candidates to treat psoriasis and small cell lung cancer are approaching late-stage study.

Continue reading Celgene is poised to break-out to the upside

<>Celgene is poised to break-out to the upside originally appeared on BloggingStocks on ...
By  Joseph Lazzaro   (+0.60%  risk: moderate)  10/09/09 Comment


Celgene (CELG): Cancer progress boosts biotech Graphic_rating_buy CELG
-2.54%
in 81 days

Filed under: Newsletters, Stock screen, Stocks to Buy

"Some sectors tend to do better than others in tough times; biotechnology often surprises investors in good times and bad," suggests Brandon Clay.

In his Invest with an Edge advisory service, the growth stock advisor looks to Celgene Corporation (NASDAQ: CELG), a player in developing cancer treatments. Here's his review.

"This sometimes-perilous market niche can make or break a portfolio depending on several factors: drug pipeline, continued investment, market factors, and government approvals.

<>"However, despite the risks, there are times wh...
By  Steven Halpern   (+3.25%  risk: moderate)  08/19/09 Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +35.25% 368
2 Gerald Greene 18.14 +70.90% 206
3 stockmarketfunding.com 17.66 +25.78% 53
4 akiralegrand 13.47 +14.32% 60
5 anup2104 12.13 +69.23% 34


POPULAR STOCKS
Symbol Company Name Sentiment
GM General Motors Corp
C Citigroup Inc
WFC Wells Fargo & Company
AIG American International Group Inc.
NVDA NVIDIA Corp
V Visa Inc

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on CELG

Visit streetinsider.com


Discussion Wall + Add  
amritadas   (+0.00%)
A FREE report on the approval of a new Gout Drug - An upcoming treatment by a small cap company for Gout to face FDA decision on approval shortly. Gout has traditionally been a difficult disease to tre
+   0 replies


More Resources

Graphic_arrow1 About Celgene Corp - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch